Comparing Real‐World Evidence With Clinical Trials in Juvenile Idiopathic Arthritis

医学 卡那努马布 观察研究 阿达木单抗 临床试验 儿科 关节炎 疾病 药物流行病学 人口 内科学 重症监护医学 回顾性队列研究 随机对照试验 少年 梅德林
作者
Stephen J. Balevic,Timothy Beukelman,Thomas A. Phillips,Colleen K. Correll,Ann McMahon,the CARRA Registry Investigators
出处
期刊:Pharmacoepidemiology and Drug Safety [Wiley]
卷期号:35 (10): e70492-e70492
标识
DOI:10.1002/pds.70492
摘要

OBJECTIVE: To compare the clinical characteristics and outcomes of children with juvenile idiopathic arthritis (JIA) treated with biologic drugs in traditional clinical trials with the real-world data (RWD) in the CARRA Registry. METHODS: This was a retrospective observational study. We reviewed data from 3192 children in the CARRA Registry with JIA exposed to adalimumab or canakinumab, 2 historical trials of polyarticular JIA participants exposed to adalimumab (n = 171 and 32), and 1 trial for canakinumab in systemic JIA (n = 43). We made matched and unmatched comparisons of demographic information and the ACR-Pedi response rate based on trial eligibility criteria. RESULTS: Very few children in the CARRA Registry would have been eligible for the historical clinical trials: < 10% for adalimumab and < 5% for canakinumab. There was a longer duration of follow-up and a wider range of body size in the CARRA Registry compared with the historical clinical trials. When matched on trial inclusion, the ACR-Pedi response rates broadly aligned with those observed in the trials for adalimumab, whereas the sample size for canakinumab limited comparisons for the response rate. CONCLUSION: Children encountered in clinical practice had wider ranges of body size and less severe disease at drug initiation. These results underscore that registration trials may be enriched for patients with more severe disease and are not fully representative of the broader JIA population who use these drugs after marketing. Real-world evidence generated from observational data may play an increasingly important role in regulatory decision making, along with the continued need for controlled clinical trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
符聪发布了新的文献求助10
刚刚
刚刚
符聪发布了新的文献求助10
刚刚
刚刚
甲沟炎发布了新的文献求助10
1秒前
北海未暖完成签到,获得积分10
1秒前
1秒前
万能图书馆的应助被知有采纳,获得10
1秒前
阿涛完成签到 ,获得积分10
1秒前
2秒前
轻松忆翠完成签到,获得积分10
3秒前
洞洞幺完成签到 ,获得积分10
3秒前
jack发布了新的文献求助10
3秒前
符聪发布了新的文献求助10
3秒前
3秒前
符聪发布了新的文献求助10
3秒前
符聪发布了新的文献求助10
3秒前
kinlo97完成签到,获得积分10
4秒前
欢呼音响发布了新的文献求助10
4秒前
大模型的应助被搞怪的芙采纳,获得10
4秒前
4秒前
小羊发布了新的文献求助10
5秒前
5秒前
JDK发布了新的文献求助30
5秒前
今后的应助被新楚采纳,获得10
6秒前
6秒前
molihuakai的应助被gsgg采纳,获得10
6秒前
俏皮的沉鱼完成签到,获得积分20
6秒前
6秒前
6秒前
王一发布了新的文献求助10
6秒前
完美世界的应助被King强采纳,获得20
7秒前
7秒前
qolke完成签到,获得积分10
7秒前
HAi完成签到,获得积分10
7秒前
mike发布了新的文献求助10
7秒前
元谷雪的应助被drizzle采纳,获得10
8秒前
Camellia完成签到,获得积分10
10秒前
syh发布了新的文献求助10
10秒前
这样说话完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417